Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody

Clinical and Experimental Immunology

Volumn 183, Issue 1, 2016, Pages 102-113

  Xue, L ^a   Hickling, T ^a   Song, R ^a   Nowak, J ^a   Rup, B ^a  

^a PFIZER INC   (United States)

Author keywords

Antigen processing and presentation; IL 21 receptor; Immunogenicity; T cell epitope; T cell proliferation

Indexed keywords

ATR 107; CD40 ANTIGEN; CD86 ANTIGEN; DRUG ANTIBODY; EPITOPE; IMMUNOGLOBULIN G; INTERLEUKIN 21 RECEPTOR; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; RECOMBINANT INTERLEUKIN 21; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ATR-107; HLA DR ANTIGEN; INTERLEUKIN 21; INTERLEUKIN DERIVATIVE; LEUKOCYTE ANTIGEN; TUMOR NECROSIS FACTOR;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; ENDOSOME; HUMAN; HUMAN CELL; IMMUNOGENICITY; INTERNALIZATION; LIGHT CHAIN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; RISK ASSESSMENT; T LYMPHOCYTE; CELL CULTURE; CELL DIFFERENTIATION; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; SECRETION (PROCESS);

ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; ANTIGENS, CD; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; ENDOSOMES; EPITOPES, T-LYMPHOCYTE; HLA-DR ANTIGENS; HUMANS; INTERLEUKINS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84955415340     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12711     Document Type: Article

References (40)

1. Wullner D, Zhou L, Bramhall E et al. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin Immunol 2010; 137:5-14.
2. Schafer JR, Jesdale BM, George JA, Kouttab NM, De Groot AS. Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. Vaccine 1998; 16:1880-4.
3. Rombach-Riegraf V, Karle AC, Wolf B et al. Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro. PLOS ONE 2014; 9:e86322.
4. Koren E, De Groot AS, Jawa V et al. Clinical validation of the 'in silico' prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol 2007; 124:26-32.
5. Vugmeyster Y, Guay H, Szklut P et al. In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus. MAbs 2010; 2:335-46.
6. Hua F, Comer GM, Stockert L et al. Anti-IL21 receptor monoclonal antibody (ATR-107): safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol 2014; 54:14-22.
7. Rosenberg AS, Worobec AS. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 1. Considering consequences of the immune response to a protein. BioPharm Int 2004; 17:22-6.
8. Rosenberg AS, Worobec AS. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 2. Considering host-specific and product-specific factors impacting immunogenicity. BioPharm Int 2004; 17:34-42.
9. Rosenberg AS, Worobec AS. A risk-based approach to immunogenicity concerns of therapeutic protein products, Part 3. Effects of manufacturing changes in immunogenicity and the utility of animal immunogenicity studies. BioPharm Int 2005; 18:32-6.
10. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010; 2:256-65.
11. Vallieres F, Girard D. IL-21 enhances phagocytosis in mononuclear phagocyte cells: identification of spleen tyrosine kinase as a novel molecular target of IL-21. J Immunol 2013; 190:2904-12.
12. Spolski R, Leonard WJ. Interleukin-21: a double-edged sword with therapeutic potential. Nat Rev Drug Discov 2014; 13:379-95.
13. Guo Y, Hill AA, Ramsey RC et al. Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody. J Transl Med 2010; 8:50.
14. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008; 26:57-79.
15. Rankin AL, MacLeod H, Keegan S et al. IL-21 receptor is critical for the development of memory B cell responses. J Immunol 2011; 186:667-74.
16. Leonard WJ, Zeng R, Spolski R. Interleukin 21: a cytokine/cytokine receptor system that has come of age. J Leukoc Biol 2008; 84:348-56.
17. Kasaian MT, Whitters MJ, Carter LL et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002; 16:559-69.
18. Desjardins M, Mazer BD. B cell memory and primary immune deficiencies: interleukin-21 related defects. Curr Opin Allergy Clin Immunol 2013; 13:639-45.
19. Young DA, Hegen M, Ma HL et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007; 56:1152-63.
20. Southwood S, Sidney J, Kondo A et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998; 160:3363-73.
21. Nielsen M, Lundegaard C, Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics 2007; 8:238.
22. Bui HH, Sidney J, Peters B et al. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 2005; 57:304-14.
23. Sturniolo T, Bono E, Ding J et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999; 17:555-61.
24. Bakdash G, Sittig SP, van Dijk T, Figdor CG, de Vries IJ. The nature of activatory and tolerogenic dendritic cell-derived signal II. Front Immunol 2013; 4:53.
25. Blanco P, Palucka AK, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 2008; 19:41-52.
26. de Saint-Vis B, Fugier-Vivier I, Massacrier C et al. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol 1998; 160:1666-76.
27. Nagorsen D, Marincola FM, Panelli MC. Cytokine and chemokine expression profiles of maturing dendritic cells using multiprotein platform arrays. Cytokine 2004; 25:31-5.
28. Wesa A, Galy A. Increased production of pro-inflammatory cytokines and enhanced T cell responses after activation of human dendritic cells with IL-1 and CD40 ligand. BMC Immunol 2002; 3:14.
29. Coates PT, Colvin BL, Hackstein H, Thomson AW. Manipulation of dendritic cells as an approach to improved outcomes in transplantation. Exp Rev Mol Med 2002; 4:1-21.
30. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13:227-42.
31. Brandt K, Bulfone-Paus S, Foster DC, Ruckert R. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 2003; 102:4090-8.
32. Yoshizaki A, Miyagaki T, DiLillo DJ et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 2012; 491:264-8.
33. Yang X, Yang J, Chu Y et al. T follicular helper cells mediate expansion of regulatory B cells via IL-21 in lupus-prone MRL/lpr mice. PLOS ONE 2013; 8:e62855.
34. Vyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol 2008; 8:607-18.
35. van Niel G, Wubbolts R, Stoorvogel W. Endosomal sorting of MHC class II determines antigen presentation by dendritic cells. Curr Opin Cell Biol 2008; 20:437-44.
36. Roche PA, Furuta K. The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol 2015; 15:203-16.
37. Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 2008; 29:319-24.
38. Chappell CP, Giltiay NV, Dresch C, Clark EA. Controlling immune responses by targeting antigens to dendritic cell subsets and B cells. Int Immunol 2014; 26:3-11.
39. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7:790-802.
40. Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004; 4:24-34.